Help Patients Save on Single-Dose XOFLUZA

Eligible patients may pay as little as $30 (up to $60 off) with the XOFLUZA coupon*

Help your patients save by offering them the XOFLUZA coupon.

Or have your patients text Rx to 96260.
Message and data rates apply.

For patients:

  1. By using this coupon, you acknowledge that you meet the eligibility criteria and will comply with the terms and conditions.
  2. Present this coupon to your pharmacy along with a valid prescription for XOFLUZA and
    • You will pay the first $30
    • Genentech will pay up to the next $60 depending on your insurance coverage

      Any additional amounts due are your responsibility.
  3. May be used twice. Valid until September 30, 2024.

If you have any questions, call 1-855-XOFLUZA.

For pharmacists:

  1. The processing information on this card can be repeatedly used for all your patients.
  2. When you apply this offer, you are certifying that the patient meets the eligibility criteria, and that you have not submitted and will not submit a claim for reimbursement under any state- or federally funded prescription insurance program for this prescription.
  3. For insured patients, process a coordination of benefits (COB/split bill) claim using the patient’s prescription insurance for the PRIMARY claim. Submit a SECONDARY claim using BIN 610020, PCN S6 and GROUP 99994457. For cash-paying or uninsured patients, submit a PRIMARY claim using BIN 610020, PCN S6, and GROUP 99994457. For help processing the coupon, please call 1-855-659-9767.


RxBIN: 610020
Group: 99994457

*Patient eligibility/terms and conditions:

  1. Program is only available for commercially insured patients. Patients using Medicare, Medicaid or any other government-funded program to pay for their Genentech medicines are not eligible.
  2. This Coupon is only available to those patients who are taking the Genentech medicine for an FDA-approved indication, and it cannot be combined with any other rebate/Coupon, free trial or similar offer for the specified prescription.
  3. The Patient or their guardian must be 18 years of age or older.
  4. It is only valid for Genentech medicines and only valid in the U.S. and U.S. Territories.
  5. The coupon is not health insurance or a benefit plan.
  6. The Program is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents where applicable (such as MA, CA).

Important Safety Information & Indication


XOFLUZA is an influenza virus polymerase acidic (PA) endonuclease inhibitor indicated for:

  • Treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours and who are:
    • otherwise healthy adults and pediatric patients 5 years of age and older, OR
    • adults and pediatric patients 12 years of age and older who are at high risk of developing influenza-related complications
  • Post-exposure prophylaxis (PEP) of influenza in patients 5 years of age and older following contact with an individual who has influenza.


Limitations of Use
Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA.

Important Safety Information

XOFLUZA is contraindicated in patients with a history of hypersensitivity to baloxavir marboxil or any of its ingredients. Serious allergic reactions have included anaphylaxis, angioedema, urticaria, and erythema multiforme.


Warnings and Precautions

 Cases of anaphylaxis, urticaria, angioedema, and erythema multiforme have been reported in postmarketing experience with XOFLUZA.  Appropriate treatment should be instituted if an allergic-like reaction occurs or is suspected.

Increased Incidence of Treatment-Emergent Resistance in Patients Less Than 5 Years of Age: XOFLUZA is not indicated in patients less than 5 years of age due to increased incidence of treatment-emergent resistance in this age group. In clinical trials, the incidence of virus with treatment-emergent substitutions associated with reduced susceptibility to baloxavir (resistance) was higher in pediatric subjects younger than 5 years of age (43%, 36/83) than in pediatric subjects ≥5 years to <12 years of age (16%, 19/117) or subjects ≥12 years of age (7%, 60/842). The potential for transmission of resistant strains in the community has not been determined.

Risk of bacterial Infections: There is no evidence of the efficacy of XOFLUZA in any illness caused by pathogens other than influenza viruses. Serious bacterial infections may begin with influenza-like symptoms or may coexist with, or occur as, a complication of influenza. XOFLUZA has not been shown to prevent such complications. Prescribers should be alert to potential secondary bacterial infections and treat them as appropriate.

Adverse Reactions

  • The most common adverse reactions (≥1%) in adult and adolescent patients (≥12 years of age) in clinical studies for acute uncomplicated influenza were diarrhea (3%), bronchitis (3%), nausea (2%), sinusitis (2%), and headache (1%).
  • The most frequently reported adverse reactions (≥5%) in pediatric patients (5 to <12 years of age) in clinical studies for acute uncomplicated influenza were vomiting (5%) and diarrhea (5%).
  • The safety profile reported in a clinical study for post-exposure prophylaxis was similar in pediatric patients ages 5 to <12 years old as that reported in adults and adolescents 12 years of age and older.

Drug Interactions

Polyvalent cations:
 Coadministration with polyvalent cation-containing products may decrease plasma concentrations of baloxavir, which may reduce XOFLUZA efficacy. Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc).


Vaccines: The concurrent use of XOFLUZA with intranasal live attenuated influenza vaccine (LAIV) has not been evaluated. Concurrent administration of antiviral drugs may inhibit viral replication of LAIV and, thereby, decrease the effectiveness of LAIV vaccination. Interactions between inactivated influenza vaccines and XOFLUZA have not been evaluated.

For additional Important Safety Information, please see the XOFLUZA full Prescribing Information.

You are encouraged to report side effects to Genentech by calling 1-888-835-2555 or to the FDA by visiting or calling 1-800-FDA-1088.